Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Disposal

8 Feb 2010 07:00

RNS Number : 7954G
CareCapital Group plc
08 February 2010
 



8 February 2010

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Sale of Part of UK Property Portfolio

 

CareCapital Group plc (AIM: CARE), the healthcare real estate developer and investor, announces that it has disposed of part of its UK property portfolio, comprising 14 primary care investment properties, through the sale of Sinclair Montrose Properties Limited ("SMP"), a wholly owned subsidiary of CareCapital (the "Disposal"), to Primary Health Investment Properties Limited ("PHP") for a consideration of £23.5 million payable in cash on completion.

 

The net cash proceeds, after the repayment of the senior debt within the SMP Group of Companies associated with these properties, will amount to approximately £4.4 million from which sum the majority of the Company's short term financing will be repaid with the balance to be used as working capital.

 

At 30 September 2009, the properties included in the Disposal were valued at £22.95 million as included in CareCapital's interim accounts. The properties' current rental income is £1.409 million per annum.

 

Additionally, CareCapital has entered into an agreement with PHP that provides for the funding and disposal on completion of further primary health care properties in CareCapital's development pipeline.

 

Dr Michael Sinclair, Chairman of CareCapital, commented: "This transaction has strengthened our balance sheet and provides a base from which to progress the opportunities in the remaining development pipeline. This pipeline, as previously disclosed, has a combined developed value of over £80 million.

 

"The Company's current development at Adlershof in Berlin, which is fully pre-let, is scheduled for completion next month and, combined with the existing Adlershof building, will provide one of the most important medical buildings in Germany with a total of over 8,000 square metres of space let to over 50 medical tenants. On completion of this building, the gross value of CareCapital's current portfolio of investment properties and completed developments will be approximately £34 million representing a net asset value for those assets in excess of £10.5 million."

 

For further information please visit www.carecapital.co.uk or contact:

 

CareCapital Group Plc

Daniel Stewart & Co. Plc

Tavistock Communications

 

 

Paul Stacey, Chief Executive

Steve Wilden, Finance Director

Simon Leathers

Simon Hudson

Paul Young

 

Tel: 020 7034 1949

Tel: 020 7776 6550

Tel: 020 7920 3150

 

pstacey@carecapital.co.uk

swilden@carecapital.co.uk

simon.leathers@danielstewart.co.uk

shudson@tavistock.co.uk

pyoung@tavistock.co.uk

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISKMGGZNNMGGZM
Date   Source Headline
30th Oct 20205:00 pmRNSTotal Voting Rights
26th Oct 20207:00 amRNSEquity fundraise of c.£7.7m
23rd Oct 20202:25 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
19th Oct 20207:00 amRNSInvestor Day Update
8th Oct 20202:06 pmRNSSecond Price Monitoring Extn
8th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202010:50 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
6th Oct 20207:00 amRNSReplacement: Grant of LTIP Options
5th Oct 20207:01 amRNSNotice of Investor Day
5th Oct 20207:00 amRNSGrant of LTIP Options
29th Sep 20207:00 amRNSDirectorate Appointment
29th Sep 20207:00 amRNSInterim Results
8th Sep 20207:00 amRNSTechnical Development Update
7th Sep 20207:00 amRNSAppointment of Joint Broker
21st Aug 20207:00 amRNSDraw down from Nerano Pharma debt facility
18th Aug 20204:30 pmRNSDirector/PDMR Shareholding
29th Jul 20202:52 pmRNSResult of AGM and Directorate Changes
2nd Jul 20207:15 amEQSHardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
29th Jun 20207:01 amRNSFinal Results for the year ended 31 December 2019
29th Jun 20207:00 amRNSStrategic funding partnership and debt facility
17th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20207:00 amRNSDirectorate Changes and Notice of Results
3rd Jun 20205:30 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
20th May 20204:30 pmRNSHolding(s) in Company
11th May 20206:01 pmRNSResult of General Meeting, Additional Subscription
21st Apr 20207:00 amRNSNotice of GM and Posting of Circular
9th Apr 20207:30 amRNSFurther re Subscription and Issue of Equity
9th Apr 20207:00 amRNSProposed Subscription to raise c.£15 million
26th Feb 20203:40 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
17th Feb 202011:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
17th Feb 20207:00 amRNSPurchase of a LIGHT proton therapy system
11th Feb 20207:00 amRNSPartnership with The London Clinic
4th Dec 20197:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
4th Dec 20197:00 amRNSTwo-Year Collaborative Research Study
3rd Dec 20195:45 pmRNSHolding(s) in Company
29th Nov 20195:00 pmRNSTotal Voting Rights
28th Nov 201910:15 amRNSHolding(s) in Company
20th Nov 20197:00 amRNSSubscription to raise c.GBP 2.7 million
11th Nov 20199:11 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
6th Nov 20193:35 pmRNSTotal Voting Rights
10th Oct 20197:00 amRNSChange of Broker
30th Sep 20195:15 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSFurther re funding for first LIGHT system
30th Sep 20197:00 amRNSHalf-year Report
9th Sep 20194:48 pmRNSExercise of Warrants and Issue of Equity
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.